Presented by:
Romaine Charles Nichols, Jr., MD
Associate Professor, University of Florida Department of Radiation Oncology
UF Health Proton Therapy Institute
Faculty Disclosure:
Romaine Charles Nichols, Jr., MD has disclosed that he has no relevant financial relationships. No one else in a position to control content has any financial relationships to disclose. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. All relevant financial relationships have been mitigated.
Release Date: November 12, 2021
Expiration Date: November 11, 2022
Target Audience: This CME is intended for healthcare professionals who care for patients with cancer, including specialty care physicians, advanced care providers, physician assistants, nurses, primary care physicians, patient navigators, and any other healthcare support providers.
Learning Objectives:
As a result of participation in this activity, participants should be able to:
- Discuss best practices of the use of proton therapy for pancreatic cancer based on current research.
- Define how proton therapy is different from conventional radiation therapy.
- Identify and determine the theoretical advantages to the use of proton therapy in the treatment of pancreatic cancer.
Requirements for successful completion: Certificates are awarded upon successful completion (80% proficiency) of the post-test.
Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Resource(s) for further study:
- Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared withthree-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer.Int J Radiat Oncol Biol Phys. Jul 15 2006;65(4):1087-1096.
- Nichols RC, Huh SH, Hoppe BS, et al. Protons safely allowcoverage of high-risk nodes for patients with regionally advanced non-small-cell lung cancer. Technol Cancer Res Treat.Aug 2011;10(4):317-322.
- Hoppe BS, Flampouri S, Henderson RH, et al. Proton therapy with concurrent chemotherapyfor non-small-cell lung cancer: technique and early results. Clin Lung Cancer. Sep 2012;13(5):352-358.
- Zhang X, Li Y,Pan X, et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulatedradiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stageIIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys. Jun 1 2010;77(2):357-366.
For additional information, please contact Christina Mershell at clmershell@floridaproton.org or call (904) 831-4034.